luveltamab tazevibulin (STRO-002) - Sutro Biopharma
STRO-004 - Sutro Biopharma
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference (GlobeNewswire) - Nov 4, 2024 - "Presentation Details:...Showcasing Clinical Update & Learnings for Luvelta Targeting Folate Receptor....Characterizing ADC Safety & Activity in Preclinical Development of STRO-004...." 
Clinical data • Preclinical • Oncology
https://www.globenewswire.com/news-release/2024/11/04/2974424/0/en/Sutro-Biopharma-Demonstrates-Meaningful-ADC-Innovation-with-Five-Presentations-at-the-15th-Annual-World-ADC-Conference.html
 
Nov 4, 2024
 
Prev Next